Patents Assigned to Astrazeneca Pharmaceuticals LP
-
Patent number: 10789558Abstract: Apparatus and methods for machine-based planning. The apparatus may cluster a plurality of geographically different resources into a plurality of clusters of proximate resources. The apparatus may calculate a cost of transporting each resource to each of a plurality of destinations. The apparatus may map each cluster to one of the destinations to determine a sum of costs of transporting all of the resources to the destinations. The apparatus may assign to each of the plurality of destinations only resources: that are mapped to the destination; for which the destination has sufficient capacity to accommodate the resources; and whose assignment to the destination does not exclude from the destination, by filling the capacity, a different resource that is: mapped to the destination; and has a net cost that is higher than a net cost of the resource of the assignment.Type: GrantFiled: May 24, 2018Date of Patent: September 29, 2020Assignee: AstraZeneca Pharmaceuticals LPInventors: Christopher Waldeck, Daniel Stavish
-
Publication number: 20200222509Abstract: Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.Type: ApplicationFiled: January 24, 2020Publication date: July 16, 2020Applicants: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Mark Fineman, Leigh Macconell, Kristin Taylor
-
Publication number: 20180333468Abstract: Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.Type: ApplicationFiled: February 5, 2018Publication date: November 22, 2018Applicants: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Mark FINEMAN, Leigh MACCONELL, Kristin TAYLOR
-
Publication number: 20180271946Abstract: The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance.Type: ApplicationFiled: February 16, 2018Publication date: September 27, 2018Applicants: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Mary L. HOUCHIN, Robin H. Lee, Hong Qi, Greg Oehrtman, Robert N. Jennings, Scott H. Coleman
-
Patent number: 9884092Abstract: Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.Type: GrantFiled: May 31, 2016Date of Patent: February 6, 2018Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Mark Fineman, Leigh MacConell, Kristin Taylor
-
Patent number: 9593154Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system.Type: GrantFiled: March 28, 2013Date of Patent: March 14, 2017Assignees: AstraZeneca Pharmaceuticals LP, Amylin Pharmaceuticals, LLCInventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Swetha Neravetla, Chengzao Sun, Manoj P. Samant, Odile E. Levy, Abhinandini Sharma, Lala Mamedova, Christopher J. Soares
-
Publication number: 20160346357Abstract: The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance.Type: ApplicationFiled: August 11, 2016Publication date: December 1, 2016Applicants: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Mary L. HOUCHIN, Robin H. LEE, Hong QI, Greg OEHRTMAN, Robert N. JENNINGS, Scott H. COLEMAN
-
Patent number: 9453063Abstract: The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.Type: GrantFiled: March 3, 2014Date of Patent: September 27, 2016Assignees: Amylin Pharmaceuticals, LLC., AstraZeneca Pharmaceuticals LPInventors: Odile Esther Levy, Michael R. Hanley, Carolyn M. Jodka, Diana Y. Lewis, Christopher J. Soares, Soumitra S. Ghosh, Lawrence J. D'Souza, David G. Parkes, Christine M. Mack
-
Patent number: 9382304Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.Type: GrantFiled: July 3, 2012Date of Patent: July 5, 2016Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Manoj P. Samant, Abhinandini Sharma, Lala Mamedova, Esther Odile Levy, Caroline Ekblad
-
Publication number: 20160120950Abstract: The present disclosure is directed to stable pharmaceutical formulations and uses thereof.Type: ApplicationFiled: October 30, 2015Publication date: May 5, 2016Applicants: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Robert N. Jennings, John T.H. Ong, Christopher A. Rhodes, Gregg Stetsko, Steven J. Prestrelski
-
Patent number: 9249181Abstract: There are provided compounds and methods for amidating the C-terminus of a polypeptide. The methods include reacting a polypeptide which includes a C-terminal thioester or C-terminal selenoester with any one of a defined set of auxiliary molecules under conditions suitable to produce a polypeptide adduct which includes the auxiliary molecule chemically bound at the C-terminal of the polypeptide. The auxiliary molecule can be a substituted or unsubstituted 2-phenyl-2-amino ethanethiol, a substituted or unsubstituted 2-phenyl-2-amino ethaneselenol, or a substituted xanthene. In the subsequent step, a portion of the auxiliary molecule is removed from the C-terminal of the polypeptide adduct and leaving the amide nitrogen under conditions suitable to form a C-terminal free amide polypeptide.Type: GrantFiled: September 8, 2011Date of Patent: February 2, 2016Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Chengzao Sun, Behrouz Bruce Forood, Gary Luo, Soumitra S. Ghosh
-
Patent number: 9248240Abstract: The present invention provides a device for injection of formulations into a patient. In one embodiment the injection is sub-cutaneous. The device is convenient for injecting viscous formulations that would otherwise clog conventional injection devices, for example formulations containing microspheres, suspensions, and other viscous substances. Generally, the device features a needle for piercing the skin, an internal chamber for holding and transmitting fluid, a plunger for applying pressure to the internal chamber, a switch for triggering withdrawal of the needle, a sheath at least partially encompassing the needle and having a flow path within the sheath, and a spring that expands when the switch is triggered, and which thereby at least partially withdraws the needle from the sheath.Type: GrantFiled: October 14, 2009Date of Patent: February 2, 2016Assignees: AstraZeneca Pharmaceuticals LP, Amylin Pharmaceuticals, LLCInventors: William J. Casey, Tyler J. Holschlag
-
Patent number: 9217022Abstract: The disclosure provides GLP-1 receptor agonist compounds having stabilized regions corresponding to alpha-helical regions of the natural peptide compounds. The disclosure also provides benzamide-containing exendin-4 analogs and alkene-constrained exendin-4 analogs, both of which have stabilized regions corresponding to alpha-helical regions of exendin-4.Type: GrantFiled: July 27, 2011Date of Patent: December 22, 2015Assignees: AstraZeneca Pharmaceuticals LP, Amylin Pharmaceuticals, LLCInventors: Josue Alfaro-Lopez, Abhinandini Sharma, Christopher J. Soares, Eugene Coats, Soumitra S. Ghosh
-
Patent number: 9133260Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.Type: GrantFiled: March 25, 2013Date of Patent: September 15, 2015Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Odile Esther Levy, Alain D. Baron, Lawrence J. D'Souza, Mary Erickson, Soumitra S. Ghosh, Michael R. Hanley, Samuel Janssen, Carolyn M. Jodka, Diana Y. Lewis, Christine M. Mack, David G. Parkes, Richard A. Pittner, Christopher J. Soares, Ved Srivastava, Andrew A. Young
-
Publication number: 20150238568Abstract: Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microspheres encapsulating the exenatide.Type: ApplicationFiled: May 13, 2015Publication date: August 27, 2015Applicants: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Mark Fineman, Leigh MacConell, Kristin Taylor
-
Patent number: 9034819Abstract: Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microspheres encapsulating the exenatide.Type: GrantFiled: February 22, 2013Date of Patent: May 19, 2015Assignees: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals, LPInventors: Mark Fineman, Leigh MacConell, Kristin Taylor
-
Patent number: 8951962Abstract: Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.Type: GrantFiled: May 17, 2013Date of Patent: February 10, 2015Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Karthryn S. Prickett, Andrew A. Young
-
Patent number: 8946149Abstract: The present invention relates generally to the novel use of cardioprotective incretin compounds (CICs) such as GLP-1 and exendin and agonists thereof, including analogs and derivatives to prevent, delay, attenuate, or ameliorate cardiac remodeling. The present invention relates to methods for using CICs for the treatment of conditions associated with cardiac remodeling. The present invention further relates to methods for using CICs for the reduction of the risk or severity of congestive heart failure.Type: GrantFiled: April 11, 2006Date of Patent: February 3, 2015Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Christen Anderson, Que Liu
-
Patent number: 8927687Abstract: The disclosure provides microcrystals of Y receptor agonists; microcrystalline pellets of Y receptor agonists, and microcrystalline suspensions of Y receptor agonists. Pharmaceutical compositions containing these microcrystals, microcrystalline pellets, and microcrystalline suspensions have prolonged pharmacokinetic profiles making them useful for once daily or once weekly administration.Type: GrantFiled: July 8, 2011Date of Patent: January 6, 2015Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventor: Steven Shijun Ren
-
Patent number: 8906849Abstract: The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.Type: GrantFiled: April 8, 2013Date of Patent: December 9, 2014Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Odile Esther Levy, Carolyn M. Jodka, Soumitra S. Ghosh, David G. Parkes, Richard A. Pittner, Lawrence J. D'Souza, John S. Ahn, Kathryn S. Prickett, Jonathan David Roth, Sean H. Adams